Medicus Pharma (MDCXW) Equity Ratio (2023 - 2025)

Medicus Pharma (MDCXW) reported Equity Ratio of 0.01 for Q4 2025, down 101.21% on a YoY basis from 0.56 in Q4 2024, and up 92.64% quarter-over-quarter from 0.09 in Q3 2025.

Medicus Pharma (MDCXW) Equity Ratio (2023 - 2025) Analysis & Trends

Medicus Pharma has reported Equity Ratio for 3 years, with the latest figure at 0.01 in Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio fell 101.21% year-over-year to 0.01; the trailing twelve-month figure through Dec 2025 stood at 0.01 (down 101.21% YoY), and the FY2025 full-year result was 0.01, down 101.21% from the prior year.
  • Equity Ratio for Q4 2025 stood at 0.01, up from 0.09 in the prior quarter.
  • The five-year high for Equity Ratio was 0.59 in Q4 2023, with the low at 0.09 in Q3 2025.
  • Historically, Equity Ratio has averaged 0.28 across 3 years, with a median of 0.33 in 2025.
  • Annual changes were most pronounced in 2024 — Equity Ratio retreated 5.45% — and 2025, when it sank 101.21%.
  • Medicus Pharma's Equity Ratio stood at 0.59 in 2023, then dropped by 5.45% to 0.56 in 2024, then plunged by 101.21% to 0.01 in 2025.
  • The last three Equity Ratio figures came in at 0.01 (Q4 2025), 0.09 (Q3 2025), and 0.27 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn -
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 0.27
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn 0.40
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn -0.05
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 0.36
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 0.10
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 0.42
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 0.43
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 0.23
10 Medicus Pharma - - - -0.01

Historic Data

Download Data
DateValue
Dec 31, 2025 -0.01
Sep 30, 2025 -0.09
Jun 30, 2025 0.27
Mar 31, 2025 0.38
Dec 31, 2024 0.56
Dec 31, 2023 0.59